In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Investment is additive to KKR’s existing health care growth strategy
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
hey were educated about the 7- step hand-washing technique trainings
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
The composition of ORAAL is protected by a granted patent in India until November 2033
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Subscribe To Our Newsletter & Stay Updated
